Vicore Announces Investment from Sanofi

September 30, 2024 1:15 PM

Vicore Pharma Holding AB (STO:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announces an investment from Sanofi in Vicore through a commitment to subscribe for shares in the ongoing rights issue corresponding to a total of approximately USD 10.0 million (approximately SEK 102.0 million). The commitment entails a subscription...

Read more

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

September 30, 2024 7:00 AM

- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - Merger anticipated to close in 1Q25BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in...

Read more

Ondine Biomedical Reports Robust Growth in H1 2024

September 30, 2024 5:05 AM

Ondine Biomedical Inc. (AIM:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce strong operational results for the first half of 2024, highlighting significant progress and expansion in its commercial and clinical endeavors.Financial figures throughout this interim report are in Canadian dollars unless otherwise specified.Operational Highlights· Commercial growth:...

Read more

Ondine Biomedical Reports Robust Growth in H1 2024

September 30, 2024 2:00 AM

Ondine Biomedical Inc. ("Ondine Biomedical", "Ondine" or the "Company") (AIM:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce strong operational results for the first half of 2024, highlighting significant progress and expansion in its commercial and clinical endeavors.Financial figures throughout this interim report are in Canadian dollars unless otherwise...

Read more

Ensysce Biosciences Receives Notice from Nasdaq

September 27, 2024 4:30 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the...

Read more

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

September 26, 2024 10:20 PM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public offering led by existing institutional investors of 4,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per share. The pre-funded warrants will be immediately exercisable and may be...

Read more

enVVeno Medical Corporation Announces Proposed Public Offering

September 26, 2024 4:05 PM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. enVVeno expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of...

Read more

SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders

September 25, 2024 9:45 AM

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has received ABBIE Technology kits pre-launch orders.Dr. David Aguilar, COO, shared that the company has received pre-launch and pre-orders for our ABBIE technology kits. This is significant miles stone for the company and we are very happy to transition from Research and Development to commercialization of...

Read more

Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

September 25, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini,...

Read more

Adolore BioTherapeutics to Present at BioSparkVA Pitch Event

September 24, 2024 8:20 AM

Adolore BioTherapeutics, Inc., ("Adolore" or the "Company"), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C. Levitt, MD, the Company's founder and Executive Chairman, Chief Medical Officer, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at BioSparkVA's BioSpark Pitch Event, hosted by...

Read more

Ensysce Biosciences Presenting at Upcoming Meetings

September 24, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in two upcoming meetings in October 2024.October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature...

Read more

Cloud Storage Security Names Kevin Hunt as Chief Technology Officer

September 24, 2024 8:00 AM

Cloud Storage Security (CSS), a leader in advanced threat detection and data loss prevention for cloud-native applications, today announced that Kevin Hunt has joined the company as chief technology officer. In this capacity, he is responsible for leading CSS's technical vision across product development, engineering, and customer experience. Hunt brings to CSS a wealth of experience in leading product teams and driving technological...

Read more

Enalare Receives FDA Clearance to Initiate the First Phase 1 Clinical Study of ENA-001 to Be Conducted in the United States

September 24, 2024 8:00 AM

PRINCETON, NJ / ACCESSWIRE / September 24, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced that is has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I clinical study of ENA-001 that supports the proposed indication for...

Read more

Biovica Announces Subscription Commitments in Ongoing TO3B Program

September 24, 2024 7:45 AM

UPPSALA, SWEDEN / ACCESSWIRE / September 24, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Monday, September 30, 2024, is the last day for subscription in Biovica's ongoing warrant program, TO3B. Note that some banks and asset managers may have an earlier deadline date for subscription than 30 September 2024. Shareholders should check this with their bank or trustee in order not to miss the chance to subscribe for shares or...

Read more

Longwood Healthcare Leaders' Flagship Meeting Boston CEO to Convene Life Science Thought Leaders Across Government, Pharma, Biotech, Academia, and Research

September 24, 2024 7:00 AM

BOSTON, MA / ACCESSWIRE / September 24, 2024 / Longwood Healthcare Leaders will convene top biopharmaceutical executives for two days of discussion and networking at Boston CEO, a leading industry meeting co-hosted by Christoph Westphal, John Maraganore, Ted Love, Marcus Schindler, Susan Hockfield, and Mathai Mammen, held at the Mandarin Oriental Hotel, Boston, October 28-29, 2024.Longwood Healthcare Leaders LogoLongwood Healthcare Leaders Logo ...

Read more

Cenna Biosciences Receives NIH NIA Phase II SBIR Award for the Early Clinical Development of Nubytide TM, a First-in-Class, Disease-Modifying Peptide Drug for the Prevention and Treatment of Alzheimer’s Disease

September 23, 2024 6:00 PM

LA JOLLA, CA / ACCESSWIRE / September 23, 2024 / Cenna Biosciences Inc., a privately-held biopharmaceutical company based in La Jolla, California, and focused on developing novel treatments for Alzheimer's disease (AD), has been awarded a Phase II SBIR grant of $2.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA), to support the early clinical development of their peptide drug NubytideTM, for the prevention and...

Read more

Biovica Signs Significant Work Order for TKa Testing Services

September 23, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / September 23, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a work order with a value of 2.2 MSEK. This is the company's largest single work order to date for TKa testing services within its Pharma Services business. The work order is signed with a US-based biotech company focused on next-generation CDK inhibitors, which since last week...

Read more

Mölnlycke(R) and Ondine Join Forces Against HAIs

September 23, 2024 2:00 AM

Ondine Biomedical Inc. (LON:OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, and Mölnlycke Health Care (Gothenburg Sweden), a world-leading MedTech company that specializes in innovative solutions for wound care and surgical procedures, are pleased to announce a strategic partnership to bring Ondine's Steriwave® nasal decolonization technology to the United Kingdom, EU, and Middle East markets.This...

Read more

DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners

September 20, 2024 9:00 AM

LIPID inCode tests patients to identify familial hypercholesterolemia and prevent cardiovascular diseaseOXFORD, ENGLAND / ACCESSWIRE / September 20, 2024 / GENinCode Plc (AIM:GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces its collaboration with The Family Heart Foundation®, UT Southwestern, and other partner members to use the LIPID inCode® monogenic and polygenic test in US Primary...

Read more

NeuroEM Therapeutics(R) Accepted into StartUp Health's Alzheimer's Moonshot Community(TM)

September 19, 2024 8:30 AM

TAMPA, FL / ACCESSWIRE / September 19, 2024 / NeuroEM Therapeutics®, a leading clinical-stage biotechnology research company focused on commercializing its proprietary Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technologies against Alzheimer's disease and cognitive decline, announced today it has been accepted as a member of StartUp Health's Alzheimer's Moonshot Community™. The invitation came following a...

Read more